Sangamo Therapeutics, Inc. (SGMO)
$
0.46
+0.01 (2.17%)
Key metrics
Financial statements
Free cash flow per share
-0.2038
Market cap
116.1 Million
Price to sales ratio
1.8218
Debt to equity
5.0705
Current ratio
0.7586
Income quality
0.5617
Average inventory
0
ROE
-3.5116
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to transforming patient lives through genomic medicines, leveraging its innovative platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company reported an income before tax of -$98,108,000.00 showcasing its pre-tax profitability. The weighted average number of shares outstanding is 201,699,000.00 highlighting the company's shareholder base. Furthermore, the company incurred an income tax expense of -$167,000.00 indicating its tax obligations. Additionally, Sangamo earned interest income of $5,861,000.00 showcasing its financial investments. The financial data pertains to the fiscal year 2024. With a focus on developing groundbreaking therapies, the company offers zinc finger protein (ZFP) technology to create zinc finger nucleases for gene modification and ZFP transcription factors to regulate gene expression. Currently, it is advancing several clinical trials, including SB-525 in Phase III for hemophilia A, ST-920 in Phase I/II for Fabry disease, and SAR445136 in Phase I/II for sickle cell disease. Other notable developments include TX200 for kidney transplant rejection, KITE-037 for cancer, and ST-501 and ST-502 targeting tauopathies and synucleinopathies, respectively. The stock is affordable at $0.46 suitable for budget-conscious investors. It has a high average trading volume of 6,982,616.00 indicating strong liquidity. With a market capitalization of $112,320,495.00 the company is classified as a small-cap player. Sangamo is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Moreover, it belongs to the Healthcare sector, driving innovation and growth. The company has established several collaborative and strategic partnerships with prominent organizations, allowing it to enhance its research and development capabilities. Sangamo Therapeutics, Inc., formerly known as Sangamo BioSciences, Inc., was incorporated in 1995 and is headquartered in Brisbane, California.
Is Sangamo Therapeutics, Inc. (SGMO) a good investment?
Investing in Sangamo Therapeutics, Inc. (SGMO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Sangamo Therapeutics, Inc. (SGMO)'s stock forecast?
Analysts predict Sangamo Therapeutics, Inc. stock to fluctuate between $0.30 (low) and $3.18 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Sangamo Therapeutics, Inc.'s market capitalization?
As of 2025-05-29, Sangamo Therapeutics, Inc.'s market cap is $112,320,495, based on 245,402,000 outstanding shares.
How does Sangamo Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Sangamo Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Sangamo Therapeutics, Inc. (SGMO) stock?
To buy Sangamo Therapeutics, Inc. (SGMO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SGMO. Place an order (Market, Limit, etc.).
What is the best time to invest in Sangamo Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Sangamo Therapeutics, Inc. perform in the last earnings report?
Revenue: $57,800,000 | EPS: -$0.49 | Growth: -66.89%.
Where can I find Sangamo Therapeutics, Inc.'s investor relations reports?
Visit https://www.sangamo.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Sangamo Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Sangamo Therapeutics, Inc. stock?
All-time high: $15.45 (2021-02-09) | All-time low: $0.29 (2023-11-13).
What are the key trends affecting Sangamo Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
18 days ago
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q1 2025 Earnings Conference Call May 12, 2025 6:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Prathyusha Duraibabu - Chief Financial Officer Conference Call Participants Nicole Germino - Truist Luis Santos - H.C. Wainwright Operator Good afternoon and welcome to the Sangamo Therapeutics First Quarter 2025 Teleconference Call.
zacks.com
18 days ago
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.27 per share a year ago.
businesswire.com
18 days ago
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results.
businesswire.com
18 days ago
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering.
businesswire.com
24 days ago
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES FIRST QUARTER 2025 EARNINGS CALL.
businesswire.com
25 days ago
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease.
zacks.com
a month ago
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
businesswire.com
a month ago
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS TO PRESENT NEUROLOGY PIPELINE ADVANCES AT THE 28TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT).
seekingalpha.com
2 months ago
Sangamo Therapeutics, Inc.'s deal with Eli Lilly to develop genomic medicines for CNS using the STAC-BBB AAV capsid brings in an $18M upfront payment and the potential to earn $1.4B in milestone payments. The Fabry Disease gene therapy program, with phase 1/2 STAAR study data expected in 1H 2025, is a major near-term catalyst for investors to keep an eye on. Positive eGFR slope data could lead to an Accelerated Approval filing of isaralgagene civaparvovec for Fabry Disease in the 2nd half of 2025.
businesswire.com
2 months ago
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM.
See all news
